Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects

References

• Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Amer Acad Dermat. 1981 Apr;4(4):471–475.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677–2686.
   PubMed Web of Science ®Google Scholar
• Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011 Feb;147(2):203–208.
   PubMedGoogle Scholar
• Jolly M, Kazmi N, Mikolaitis RA, et al. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. J Am Acad Dermatol. 2013 Apr;68(4):618–623.
   PubMed Web of Science ®Google Scholar
• Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 May;64(5):849–858.
   PubMed Web of Science ®Google Scholar
• Vasquez R, Wang D, Tran QP, et al. A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. Br J Dermatol. 2013 Jan;168(1):145–153.
   PubMed Web of Science ®Google Scholar
• Chang AY, Ghazi E, Okawa J, et al. Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol. 2013;149(1):104–106.
   PubMed Web of Science ®Google Scholar
• Wahie S, McColl E, Reynolds NJ, et al. Measuring disease activity and damage in discoid lupus erythematosus. Br J Dermatol. 2010 May;162(5):1030–1037.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010 Jul;163(1):83–92.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Wozniacka A, Szepietowski JC, et al. Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol. J Invest Dermatol. 2011 Aug;131(8):1622–1630.
   PubMed Web of Science ®Google Scholar
• Ruland V, Haust M, Stilling RM, et al. Updated analysis of standardized photoprovocation in patients with cutaneous lupus erythematosus. Arthritis Care Res. 2013 May;65(5):767–776.
   Web of Science ®Google Scholar
• Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):391–404.
   PubMed Web of Science ®Google Scholar
• Zahn S, Graef M, Patsinakidis N, et al. Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus. Exp Dermatol. 2014 Jul;23(7):516–518.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011 Jan;64(1):37–48.
   PubMed Web of Science ®Google Scholar
• Patsinakidis N, Wenzel J, Landmann A, et al. Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls. Exp Dermatol. 2012 Dec;21(12):958–961.
   PubMed Web of Science ®Google Scholar
• Yang SY, Bernstein I, Lin DQ, et al. Photoprotective habits of patients with cutaneous lupus erythematosus. J Am Acad Dermatol. 2013 Jun;68(6):944–951.
   PubMed Web of Science ®Google Scholar
• Gutmark EL, Lin DQ, Bernstein I, et al. Sunscreen use in patients with cutaneous lupus erythematosus. Br J Dermatol. 2015 Sep;173(3):831–834.
   PubMed Web of Science ®Google Scholar
• Fenton L, Dawe R, Ibbotson S, et al. Impact assessment of energy-efficient lighting in patients with lupus erythematosus: a pilot study. Br J Dermatol. 2014 Mar;170(3):694–698.
   PubMed Web of Science ®Google Scholar
• Tiao J, Werth VP Cutaneous lupus erythematosus flare following exposure to surgical light during a dental procedure. BMJ case reports;2015.
   Google Scholar
• Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2012 Mar;148(3):317–322.
   PubMedGoogle Scholar
• Kuhn A, Sigges J, Biazar C, et al. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol. 2014 Sep;171(3):571–579.
   PubMed Web of Science ®Google Scholar
• Bockle BC, Sepp NT. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus. 2015 Jun;24(7):669–674.
   PubMed Web of Science ®Google Scholar
• Werth VP, Khamashta MA, Illei GG, et al. Smoking is associated with more severe skin disease in subjects with moderate to severe systemic lupus erythematosus (SLE). Arthritis Rheum. 2013;65(S10):2512.
   Google Scholar
• Chasset F, Frances C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015 Apr;72(4):634–639.
   PubMed Web of Science ®Google Scholar
• Kwatra SG. Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus. J Am Acad Dermatol. 2015 Aug;73(2):e79.
   Google Scholar
• Wahie S, Daly AK, Cordell HJ, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131(10):1981–1986.
   PubMed Web of Science ®Google Scholar
• Marzano AV, Lazzari R, Polloni I, et al. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011 Aug;165(2):335–341.
   PubMed Web of Science ®Google Scholar
• Gronhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012 Aug;167(2):296–305.
   PubMed Web of Science ®Google Scholar
• Liakou AI, Brunner M, Theodorakis MJ, et al. Recurrent subacute cutaneous lupus erythematosus following exposure to different drugs. Acta Derm Venereol. 2011 Sep;91(5):586–587.
   PubMed Web of Science ®Google Scholar
• Cutillas-Marco E, Marquina-Vila A, Grant WB, et al. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity. Lupus. 2014 Jun;23(7):615–623.
   PubMed Web of Science ®Google Scholar
• Drozdenko G, Heine G, Worm M. Oral vitamin D increases the frequencies of CD38+ human B cells and ameliorates IL-17-producing T cells. Exp Dermatol. 2014 Feb;23(2):107–112.
   PubMed Web of Science ®Google Scholar
• De Azevedo Silva J, Monteiro Fernandes K, Tres Pancotto JA, et al. Vitamin D receptor (VDR) gene polymorphisms and susceptibility to systemic lupus erythematosus clinical manifestations. Lupus. 2013 Oct;22(11):1110–1117.
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr., Martin JS, Eichorn P, et al. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis. 1980 Mar;25(3):281–285.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011 Dec;65(6):e179–93.
   PubMedGoogle Scholar
• Sticherling M. Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus. Biologics: Targets & Therapy. 2011;5:21–31.
   PubMedGoogle Scholar
• Avgerinou G, Papafragkaki DK, Nasiopoulou A, et al. Effectiveness of topical calcineurin inhibitors as monotherapy or in combination with hydroxychloroquine in cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol: JEADV. 2012 Jun;26(6):762–767.
   PubMed Web of Science ®Google Scholar
• Pothinamthong P, Janjumratsang P. A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. J Med Assoc Thai. 2012 Jul;95(7):933–940.
   PubMedGoogle Scholar
• Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled tria l. J Am Acad Dermatol. 2011 Jul;65(1):54-64, 64 e1-2.
   Web of Science ®Google Scholar
• Milam EC, Ramachandran S, Franks AG Jr. Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3. JAMA Dermatology. 2015 Oct 1;151(10):1113–1116.
   PubMed Web of Science ®Google Scholar
• May E, Asadullah K, Zugel U. Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):377–393.
   PubMedGoogle Scholar
• Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem. 2001 Nov;8(13):1661–1679.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Slatopolsky E. Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med. 2008 Dec;29(6):433–452.
   PubMed Web of Science ®Google Scholar
• Callen JP. Cutaneous lupus erythematosus: a personal approach to management. Australas J Dermatol. 2006 Feb;47(1):13–27.
   PubMed Web of Science ®Google Scholar
• Knott HM, Martinez JD. Innovative management of lupus erythematosus. Dermatol Clin. 2010 Jul;28(3):489–499.
   PubMed Web of Science ®Google Scholar
• Callen JP. Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol. 2002 Apr;16(2):245–264.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011 Feb;118(2):415–422.
   PubMed Web of Science ®Google Scholar
• Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997 Aug;40(8):1482–1486.
   PubMed Web of Science ®Google Scholar
• Finbloom DS, Silver K, Newsome DA, et al. Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol. 1985 Aug;12(4):692–694.
   PubMed Web of Science ®Google Scholar
• Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015 Oct;23(5):231–269.
   PubMed Web of Science ®Google Scholar
• Wahie S, Meggitt SJ. Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus. Br J Dermatol. 2013 Sep;169(3):653–659.
   PubMed Web of Science ®Google Scholar
• Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol. 2011;147(11):1261–1267.
   PubMedGoogle Scholar
• Farhangian ME, Huang WW, Feldman SR. Adherence to oral and topical medications in cutaneous lupus erythematosus is not well characterized. Dermatol Ther. 2015 Jun;5(2):91–105.
   Google Scholar
• Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329–340.
   PubMed Web of Science ®Google Scholar
• Frances C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012;148(4):479–484.
   PubMedGoogle Scholar
• Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. J Am Acad Dermatol. 2012 Sep;67(3):e123–6.
   Google Scholar
• D’Erme AM, Milanesi N, Difonzo EM, et al. Treatment of refractory subacute cutaneous lupus erythematosus with oral isotretinoin: a valid therapeutic option. Dermatol Ther. 2012 May-Jun;25(3):281–282.
   PubMed Web of Science ®Google Scholar
• Lospinoso DJ, Fernelius C, Edhegard KD, et al. Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin. Lupus. 2013 Jul;22(8):851–854.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol. 2011 Dec;65(6):e195–213.
   PubMedGoogle Scholar
• Wenzel J, Brahler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005 Jul;153(1):157–162.
   PubMed Web of Science ®Google Scholar
• Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998;18(2):59–62.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Specker C, Ruzicka T, et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2002 Apr;46(4):600–603.
   PubMed Web of Science ®Google Scholar
• Bohm L, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology. 1997;194(3):307–308.
   PubMed Web of Science ®Google Scholar
• Goldstein E, Carey W. Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol. 1994 Jul;130(7):938–939.
   PubMedGoogle Scholar
• Islam MN, Hossain M, Haq SA, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2012 Feb;15(1):62–68.
   PubMed Web of Science ®Google Scholar
• Klein A, Vogt T, Wenzel SM, et al. Cyclosporin combined with methotrexate in two patients with recalcitrant subacute cutaneous lupus erythematosus. Australas J Dermatol. 2011 Feb;52(1):43–47.
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Nishiyama S, Aita T, et al. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus. Mod Rheumatol /The Japan Rheum Assoc. 2013 Jul;23(4):659–666.
   PubMed Web of Science ®Google Scholar
• Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014 Mar;23(3):225–235.
   PubMed Web of Science ®Google Scholar
• Fortin PR, Abrahamowicz M, Ferland D, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Dec 15;59(12):1796–1804.
   PubMed Web of Science ®Google Scholar
• Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011 Oct;65(4):717–721.
   PubMed Web of Science ®Google Scholar
• Sadlier M, Kirby B, Lally A. Mycophenolate mofetil and hydroxychloroquine: an effective treatment for recalcitrant cutaneous lupus erythematosus. J Am Acad Dermatol. 2012 Jan;66(1):160-1; author reply 61-2.
   PubMed Web of Science ®Google Scholar
• Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011 Aug;13(4):300–307.
   PubMed Web of Science ®Google Scholar
• Liu KL, Shen JL, Yang CS, et al. Bullous systemic lupus erythematosus in a child responding to dapsone. Pediatr Dermatol. 2014 Jul-Aug;31(4):e104–6.
   Google Scholar
• Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012 Mar;166(3):616–623.
   PubMed Web of Science ®Google Scholar
• Baret I, De Haes P. Thalidomide: still an important second-line treatment in refractory cutaneous lupus erythematosus? J Dermatolog Treat. 2015 Apr;26(2):173–177.
   PubMed Web of Science ®Google Scholar
• Frankel HC, Sharon VR, Vleugels RA, et al. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol. 2013 Nov;52(11):1407–1409.
   PubMedGoogle Scholar
• Cortes-Hernandez J, Avila G, Vilardell-Tarres M, et al. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012;14(6):R265.
   Google Scholar
• Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol. 2012 Apr;66(4):571–582.
   PubMed Web of Science ®Google Scholar
• Okon L, Rosenbach M, Krathen M, et al. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: efficacy and safety in a 52-week trial. J Am Acad Dermatol. 2014 Mar;70(3):583–584.
   PubMed Web of Science ®Google Scholar
• Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014 Oct;44(2):175–185.
   PubMed Web of Science ®Google Scholar
• Hofmann SC, Leandro MJ, Morris SD, et al. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus–report of 17 cases and review of the literature. Lupus. 2013 Aug;22(9):932–939.
   PubMed Web of Science ®Google Scholar
• Ezeonyeji AN, Isenberg DA. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology. 2012 Mar;51(3):476–481.
   PubMed Web of Science ®Google Scholar
• Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis & Rheumatology. 2015;67(6):1586–1591.
   PubMed Web of Science ®Google Scholar
• Fanto M, Salemi S, Socciarelli F, et al. A case of subacute cutaneous lupus erythematosus in a patient with mixed connective tissue disease: successful treatment with plasmapheresis and rituximab. Case Rep Rheumatol. 2013;2013:857694.
   PubMedGoogle Scholar
• Cieza-Diaz DE, Aviles-Izquierdo JA, Ceballos-Rodriguez C, et al. Refractory subacute cutaneous lupus erythematosus treated with rituximab. Actas Dermosifiliogr. 2012 Jul-Aug;103(6):555–557.
   PubMedGoogle Scholar
• Moreno-Suarez F, Pulpillo-Ruiz A. Rituximab for the treatment of lupus erythematosus panniculitis. Dermatol Ther. 2013 Sep-Oct;26(5):415–418.
   PubMed Web of Science ®Google Scholar
• Alsanafi S, Kovarik C, Mermelstein AL, et al. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011 Apr;17(3):142–144.
   PubMed Web of Science ®Google Scholar
• Borba HH, Wiens A, De Souza TT, et al. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. Biodrugs. 2014 Apr;28(2):211–228.
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Callejas-Rubio JL, Rios-Fernandez R, et al. Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody. Indian J Dermatol Venereol Leprol. 2014 Sep-Oct;80(5):477–478.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011 Feb 26;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930.
   PubMed Web of Science ®Google Scholar
• Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov;71(11):1833–1838.
   PubMed Web of Science ®Google Scholar
• Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014 May;73(5):838–844.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb;41(2):300–309.
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343–1349.
   PubMed Web of Science ®Google Scholar
• De Souza A, Ali-Shaw T, Strober BE, et al. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol. 2011 Aug;147(8):896–898.
   PubMedGoogle Scholar
• Dahl C, Johansen C, Kragballe K, et al. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol. 2013 May;93(3):368–369.
   PubMed Web of Science ®Google Scholar
• Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus. 2012 Aug;21(9):1007–1010.
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013 Oct;65(10):2661–2671.
   PubMed Web of Science ®Google Scholar
• Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol. 2012 Mar;18(2):92–95.
   PubMed Web of Science ®Google Scholar
• Juptner M, Zeuner R, Schreiber S, et al. Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment. Lupus. 2014 Apr;23(4):428–430.
   PubMed Web of Science ®Google Scholar
• Furie R, Merrill JT, Werth VP, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe systemic lupus erythematosus. Arthritis Rheumatol. 2015;67((suppl):10.
   Google Scholar
• Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905–1913.
   PubMed Web of Science ®Google Scholar
• Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013 Apr;65(4):1011–1021.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Safety and efficacy of Sifalimumab, an anti IFN-alpha monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-208562 [Epub 2016 Mar 23].
   Google Scholar
• Werth V, Fiorentino D, Cohen S, et al. A phase I single-dose crossover study to evaluate the safety, toelrability, pharmacokinetics, pharmacodyanmics, and clinical efficacy of AMG 811 (anti-IFN-gamma) in subjects with discoid lupus erythematosus [abstract]. Arthritis Rheum. 2013;65(Suppl 10):1608.
   Google Scholar
• Belmont HM. Treatment of systemic lupus erythematosus - 2013 update. Bull Hosp Jt Dis. 2013;71(3):208–213.
   Google Scholar
• Diez MT, Boixeda P, Moreno C, et al. Histopathology and immunohistochemistry of cutaneous lupus erythematosus after pulsed dye laser treatment. Dermatol Surg. 2011 Jul;37(7):971–981.
   PubMed Web of Science ®Google Scholar
• Truchuelo MT, Boixeda P, Alcantara J, et al. Pulsed dye laser as an excellent choice of treatment for lupus tumidus: a prospective study. J Eur Acad Dermatol Venereology: JEADV. 2012 Oct;26(10):1272–1279.
   PubMed Web of Science ®Google Scholar
• Yelamos O, Roe E, Baselga E, et al. Pediatric cutaneous lupus erythematosus treated with pulsed dye laser. Pediatr Dermatol. 2014 Jan-Feb;31(1):113–115.
   PubMedGoogle Scholar
• Park KY, Lee JW, Li K, et al. Treatment of refractory discoid lupus erythematosus using 1,064-nm long-pulse neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2011 Jul;37(7):1055–1056.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang W, Li F, et al. Octreotide for the treatment of systemic lupus erythematosus: clinical effects and an in vitro study on its therapeutic mechanism. Lupus. 2011 Oct;20(11):1172–1181.
   PubMed Web of Science ®Google Scholar
• Sugita K, Kabashima R, Kawakami C, et al. Therapeutic efficacy of mizoribine for discoid lupus erythematosus with normalized frequency of circulating T helper 17 cells. Clin Exp Dermatol. 2011 Apr;36(3):315–317.
   PubMed Web of Science ®Google Scholar
• Stohl W, Merrill JT, Looney RJ, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17:215.
   PubMed Web of Science ®Google Scholar
• Ky C, Swasdibutra B, Khademi S, et al. Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study. Dermatol Reports. 2015 Mar 16;7(1):5804.
   PubMed Web of Science ®Google Scholar
• Collins E, Gilkeson G. Hematopoetic and mesenchymal stem cell transplantation in the treatment of refractory systemic lupus erythematosus–where are we now? Clin Immunology. 2013 Sep;148(3):328–334.
   PubMed Web of Science ®Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Autologous polyclonal tregs for lupus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5]. Available from:: https://clinicaltrials.gov/ct2/show/NCT02428309 NLM Identifier: NCT02428309
   Google Scholar
• Ablynx. A phase II study to evaluate safety and efficacy of ALX-0061 in subjects with systemic lupus erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US; 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02437890?term=“cutaneous+lupus”&recr=Open&rank=16. NLM Identifier: NCT02437890
   Google Scholar
• Actelion. Clinical trial to evaluate the PK, PD, biological activity and safety of ACT-334441 in SLE. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02472795?term=NCT02472795&rank=1. NLM Identifier: NCT02472795.
   Google Scholar
• Amgen. Single ascending dose study of AMG 570 in healthy subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2016. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02618967?term=NCT02618967&rank=1. NLM Identifier: NCT02618967
   Google Scholar
• Assistance Publique - Hôpitaux de Paris; Iltoo Pharma. Induction of regulatory t cells by low dose il2 in autoimmune and inflammatory diseases (TRANSREG). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2014. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT01988506?term=NCT01988506&rank=1. NLM Identifier: NCT01988506
   Google Scholar
• AstraZeneca; PRA Health Sciences. Efficacy and safety of anifrolumab compared to placebo in adult subjects with active systemic lupus erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02446899?term=NCT02446899&rank=1. NLM Identifier: NCT02446899
   Google Scholar
• Ben Chong; Daavlin Corporation. Low-dose UVA1 radiation in cutaneous lupus patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2012. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/record/NCT01776190?term=“cutaneous+lupus”&recr=Open&rank=2. NLM Identifier: NCT01776190
   Google Scholar
• Biogen. Study evaluating the safety, tolerability, and pharmacokinetics of single doses and multiple doses of BIIB059 in healthy volunteers and participants with systemic lupus erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2014. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02106897?term=NCT02106897&rank=1. NLM Identifier: NCT02106897
   Google Scholar
• Biotest. Proof-of-concept study with BT063 in subjects with systemic lupus erythematosus (BT063 in SLE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02554019?term=NCT02554019&rank=1. NLM Identifier: NCT02554019
   Google Scholar
• Bristol-Myers Squibb. Safety and efficacy study of a biologic to treat systemic lupus erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2014. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/record/NCT02265744?term=“cutaneous+lupus”&recr=Open&rank=17. NLM Identifier: NCT02265744
   Google Scholar
• Celgene Corporation. A pilot study of CC-220 to treat systemic lupus erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2014. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02185040?term=“cutaneous+lupus”&recr=Open&rank=12. NLM Identifier: NCT02185040
   Google Scholar
• Charite University, Berlin, Germany; Prof. Dr. med. Falk Hiepe (Charité, internal medicine /Rheumathology). Therapy of antibody-mediated autoimmune diseases by bortezomib (TAVAB) (TAVAB). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2014. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02102594?term=NCT02102594&rank=1. NLM Identifier: NCT02102594.
   Google Scholar
• EMD Serono. Efficacy and safety of atacicept in systemic lupus erythematosus (ADDRESS II). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2013. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT01972568?term=NCT01972568&rank=1. NLM Identifier: NCT01972568
   Google Scholar
• EMD Serono. MSC2364447C phase 1b in systemic lupus erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02537028?term=NCT02537028&rank=1. NLM Identifier: NCT02537028
   Google Scholar
• Immunomedics, Inc.; United States Department of Defense. Phase Ib study of SC milatuzumab in SLE. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT01845740?term=lupus&recr=Open&no_unk=Y&cond=lupus+erythematosus&rank=7. NLM Identifier: NCT01845740
   Google Scholar
• ImmuPharma. A 52-week, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with systemic lupus erythematosus (LUPUZOR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02504645?term=NCT02504645&rank=1. NLM Identifier: NCT02504645
   Google Scholar
• Janssen Research & Development, LLC. A phase 2a, efficacy and safety study of Ustekinumab in systemic lupus erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5]. Available from: https://clinicaltrials.gov/ct2/show/NCT02349061?term=NCT02349061&rank=1. NLM Identifier: NCT02349061
   Google Scholar
• Medical University of South Carolina. A controlled trial of allogeneic mesenchymal stem cells for the treatment of refractory lupus (MscISLE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2016. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02633163?term=NCT02633163&rank=1. NLM Identifier: NCT02633163
   Google Scholar
• Mitsubishi Tanabe Pharma Corporation. Exploratory study of MT-1303 in systemic lupus erythematosus patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02307643?term=NCT02307643&rank=1. NLM Identifier: NCT02307643
   Google Scholar
• Nantes University Hospital. Autologous EBV-specific cytotoxic T cells for the treatment of systemic lupus erythematosus (SLE) (LUPUS CTL EBV). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2016. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02677688?term=NCT02677688&rank=1. NLM Identifier: NCT02677688
   Google Scholar
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Omalizumab for lupus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2012. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT01716312?term=NCT01716312&rank=1. NLM Identifier: NCT01716312
   Google Scholar
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02535689?term=NCT02535689&rank=1. NLM Identifier: NCT02535689
   Google Scholar
• Northwell Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Nelfinavir in systemic lupus erythematosus (NISLE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2014. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02066311?term=NCT02066311&rank=1. NLM Identifier: NCT02066311
   Google Scholar
• Oklahoma Medical Research Foundation. Dipyridamole assessment for flare reduction in systemic lupus erythematosus (SLE) (DARE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2013. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/record/NCT01781611?term=“cutaneous+lupus”&recr=Active%2C+not+recruiting&rank=1. NLM Identifier: NCT01781611
   Google Scholar
• Resolve Therapeutics. A phase 2a of RSLV-132 in subjects with systemic lupus erythematosus (SLE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2016. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02660944?term=“cutaneous+lupus”&recr=Open&rank=13. NLM Identifier: NCT02660944
   Google Scholar
• Sanofi. Pharmacodynamics assessment study after single subcutaneous dose of SAR113244 versus placebo in lupus male and female patients. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02331810?term=NCT02331810&rank=1. NLM Identifier: NCT02331810
   Google Scholar
• Seattle Genetics, Inc. Dose ranging study of brentuximab vedotin in adults with lupus. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2015. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02533570?term=NCT02533570&rank=1. NLM Identifier: NCT02533570
   Google Scholar
• University of Leeds; National Institute for Health Research, United Kingdom; Pfizer; Clinical Trials Research Unit, Leeds. Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2016. [cited 2016 Mar 5] Available from: https://clinicaltrials.gov/ct2/show/NCT02656082?term=lupus&recr=Open&no_unk=Y&cond=lupus+erythematosus&rank=1. NLM Identifier: NCT02656082
   Google Scholar
• Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014 Aug 7;371(6):507–518.
   PubMed Web of Science ®Google Scholar
• An J, Woodward JJ, Sasaki T, et al. Cutting edge: antimalarial drugs inhibit IFN-beta production through blockade of cyclic GMP-AMP synthase-DNA interaction. J Immunology 2015 May 1;194(9):4089–4093.
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011 Apr 15;186(8):4794–4804.
   PubMed Web of Science ®Google Scholar
• Friedman A, Putterman C, Blecher K, et al. The TWEAK/Fn14 as a novel therapeutic target for cutaneous lupus erythematosus. J Am Acad Dermatol. 2012;66(4):AB134.
   Google Scholar
• Doerner JL, Wen J, Xia Y, et al. TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus. J Invest Dermatol. 2015 Aug;135(8):1986–1995.
   PubMed Web of Science ®Google Scholar
• Zahn S, Rehkamper C, Ferring-Schmitt S, et al. Interferon-alpha stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. Br J Dermatol. 2011 Nov;165(5):1118–1123.
   PubMed Web of Science ®Google Scholar
• Saenz-Corral CI, Vega-Memije ME, Martinez-Luna E, et al. Apoptosis in chronic cutaneous lupus erythematosus, discoid lupus, and lupus profundus. Int J Clin Exp Pathol. 2015;8(6):7260–7265.
   PubMed Web of Science ®Google Scholar
• Toberer F, Sykora J, Gottel D, et al. Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray. Exp Dermatol. 2013 Oct;22(10):656–659.
   PubMed Web of Science ®Google Scholar
• Schmitz MK, Botte DA, Sotto MN, et al. Increased corticotropin-releasing hormone (CRH) expression in cutaneous lupus lesions. Lupus. 2015 Jul;24(8):854–861.
   PubMed Web of Science ®Google Scholar
• Hegazy A, Barakat AF, Gayyar El MA, et al. Prevalence and clinical significance of anti-C1q antibodies in cutaneous and systemic lupus erythematosus. Egypt J Med Hum Genet. 2012;13(2):167–171.
   Google Scholar
• Qin M, Guo Y, Jiang L, et al. Elevated levels of serum sCXCL16 in systemic lupus erythematosus; potential involvement in cutaneous and renal manifestations. Clin Rheumatol. 2014 Nov;33(11):1595–1601.
   PubMed Web of Science ®Google Scholar
• Miao CG, Yang JT, Yang YY, et al. Critical role of DNA methylation in the pathogenesis of systemic lupus erythematosus: new advances and future challenges. Lupus. 2014 Jul;23(8):730–742.
   PubMed Web of Science ®Google Scholar
• Guo Y, Sawalha AH, Lu Q. Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application. Clin Immunol. 2014 Nov;155(1):79–90.
   PubMed Web of Science ®Google Scholar
• Kunz M, Konig IR, Schillert A, et al. Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. Exp Dermatol. 2015 Jul;24(7):510–515.
   PubMed Web of Science ®Google Scholar